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Background
The primary and secondary end-points of TITAN were
met: at week (wk) 48, significantly more DRV/r than LPV/
r patients (pts) had VL <400 cp/mL (77 vs. 68%; diff. 9%,
95% CI 2 – 16%; PP non-inferiority p < 0.001; ITT superi-
ority p = 0.008). Final wk 96 data are shown.
Methods
Treatment-experienced, LPV-naïve, HIV-1-infected pts
(VL>1,000 cp/mL) on stable HAART or off-treatment for
≥12 wks were randomised to DRV/r 600/100 mg BID, or
LPV/r 400/100 mg BID, + OBR (≥2 NRTIs/NNRTIs) for 96
wks.
Summary of results
595 pts enrolled (79% male; median 40 yrs; mean base-
line VL 4.30 log10cp/mL; median CD4 232 cells/mm3);
31.4% were PI-naïve; 81.8% susceptible to ≥4 PIs. At wk
96, significantly more DRV/r than LPV/r pts achieved
VL<400 cp/mL (66.8% vs. 58.9% [ITT-TLOVR]; diff. 7.9%,
95% CI 0.1 – 15.6), confirming non-inferiority (p <
0.001) and superiority of DRV/r over LPV/r (p = 0.034). At
wk 96, 60.4% of DRV/r pts achieved VL<50 cp/mL com-
pared to 55.2% of LPV/r pts (ITT-TLOVR; diff. 5.2%, 95%
CI -2.8 – 13.1). Virologic failure (VF; defined as >400 cp/
mL) was less frequent with DRV/r compared to LPV/r
(13.8 vs. 25.6%). Median CD4 increase was 81 and 93
cells/mm3 for DRV/r and LPV/r groups, respectively. Sig-
nificantly more DRV/r than LPV/r pts with ≥1 baseline pri-
mary PI mutation achieved VL<50 cp/ml (68.0 vs. 37.6%;
diff 30.4%, 95% CI 16.4 – 43.3; p < 0.001). The same was
true in pts with previous use of ≥1 PI (62.3 vs. 49.0%; diff
13%, 95% CI 3.6 – 22.6; p < 0.007). The incidence of
treatment-related diarrhea of at least moderate intensity
(≥Grade 2) was lower in DRV/r pts compared with LPV/r
pts (8.1 vs. 15.2%, p = 0.007). Rash was more common in
DRV/r pts (3.4 vs. 1.0%) but infrequently led to discontin-
uation (1%). Most Grade 2 to 4 adverse events (AEs), at
least possibly related to DRV/r or LPV/r, occurring in ≤1%
pts during therapy, were comparable between groups.
Serious AEs were reported for 13.8% (DRV/r) and 16.5%
(LPV/r) of pts. The incidence of AEs leading to discontin-
uation was low (8.1% both groups). Changes in triglycer-
ides and total cholesterol from baseline were less
pronounced in DRV/r pts.
Conclusion
In this final 96-wk analysis, the primary end-point was
maintained, showing non-inferiority and superiority to
LPV/r in virologic response. DRV/r pts were half as likely
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to experience virologic failure and showed more favoura-
ble GI and lipid profiles than LPV/r pts. Rash was more
common in DRV/r pts than LPV/r pts, but infrequently led
to discontinuations.Page 2 of 2
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